Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NextCure Inc (NXTC)
NASDAQ:NXTC
Holding NXTC?
Track your performance easily
NXTC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $2.57
Previous Close$1.4
Volume20.96K
Average Volume (3M)49.84K
Market Cap
$39.17M
Enterprise Value-$41.68M
Total Cash (Recent Filing)$86.44M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Oct 31, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding27,975,840
10 Day Avg. Volume51,961
30 Day Avg. Volume49,845
Standard Deviation0.22
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.47
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.66
Forecast
1Y Price Target
$3.50Price Target Upside144.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
NextCure News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNextcure ended the second quarter with $86M in cash, supporting operations into the second half of 2026.
Study ResultsUpdated Phase Ib study results showed early signs of activity for NC410 + pembro in patients with colorectal and ovarian cancer, which are notoriously difficult to treat.
Treatment EfficacyBoth patients had over 70% tumor reduction, with one surpassing 12 months on treatment and still ongoing, indicating durable responses.
Bears Say
Clinical TrialsThe new update did not include any additional responses, leading to a total ORR of 5.4%.
Financial PerformanceThe PFS for the initial 19 patients was noted to be 8.1 months, which was found to be very encouraging.
PartnershipsDue to limited resources, Nextcure will attempt to partner earlier stage programs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $0.98 and its highest was $2.57 in the past 12 months.
What is NextCure Inc’s market cap?
Currently, no data Available
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Aug 01, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.377 by -$0.173.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -$0.35.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 27,975,840 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.377. Following the earnings report the stock price went down -0.621%.
Which hedge fund is a major shareholder of NextCure Inc?
Among the largest hedge funds holding NextCure Inc’s share is Harbourvest Partners Llc. It holds NextCure Inc’s shares valued at 16K.
---
NextCure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (144.76% Upside)
$3.50 (144.76% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.26%
12-Months-Change
Fundamentals
Return on Equity
-54.74%
Trailing 12-Months
Asset Growth
-33.11%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.
---
NXTC Stock 12 Month Forecast
Average Price Target
$3.50
▲(144.76% Upside)
Technical Analysis
Best Analysts Covering NXTC
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-21.36%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.36% per trade.
---